Engineered OX40L CAR-Tregs (v2.1)

Engineered OX40L CAR-Tregs (v2.1) is a next-generation cell therapy developed by Regatta Bio (also known as Regatta Medical) for the treatment of transplantation-related conditions and autoimmune diseases. The therapy consists of regulatory T cells (Tregs) genetically modified to express a chimeric antigen receptor (CAR) that targets the OX40 ligand (OX40L), a co-stimulatory protein expressed on activated antigen-presenting cells (APCs). To maintain the regulatory phenotype, the CAR construct is placed under the control of a synthetic FOXP3 promoter. These CAR-Tregs are further engineered to be IL-2 independent, which enhances their survival and suppressive potency in the absence of exogenous IL-2 or in the presence of immunosuppressive drugs. The mechanism of action involves the recognition of OX40L on activated immune cells, leading to the upregulation of regulatory proteins and the removal of OX40L from target cells via trogocytosis, thereby suppressing immune activation and promoting long-term immune tolerance.

Other names

OX40L-CAR-TregsOX-40L-CAR-TregsOX 40L-CAR-TregsOX40L-targeted chimeric antigen receptor regulatory T cellsOX-40L-targeted chimeric antigen receptor regulatory T cellsOX 40L-targeted chimeric antigen receptor regulatory T cellsOX40L-engineered chimeric antigen receptor regulatory T cellsOX-40L-engineered chimeric antigen receptor regulatory T cellsOX 40L-engineered chimeric antigen receptor regulatory T cells